Proposal for generating new beta cells in a muted immune environment for type 1 diabetes

Claresa Levetan, Paolo Pozzilli, Lois Jovanovic, Desmond Schatz, Claresa Levetan, Paolo Pozzilli, Lois Jovanovic, Desmond Schatz

Abstract

Background: Over the past decade, many immune tolerance agents have shown promise in the non-obese diabetic mouse model for prevention and reversal of type 1 diabetes but have not been successful in clinical trials among recently diagnosed type 1 patients. The trials from decades ago using Cyclosporine A in significantly lower dosages than used for organ transplantation and in similar dosages that have increased T regulatory cell populations in conditions such as atopic dermatitis, demonstrated very high initial insulin-free remission rates when administered immediately after diagnosis. Over time, all newly diagnosed type 1 patients given Cyclosporine A required insulin. Human trials with immune tolerance agents suggest that in addition to an immune tolerance agent, a beta cell regeneration agent may also be necessary to induce long-lasting remission among patients with recent onset type 1 diabetes.

Methods: A randomized, double-blind prospective trial among recent onset type 1 diabetes patients has been designed using Cyclosporine A and a proton-pump inhibitor, which increases gastrin levels and has been shown to work through the Reg receptor to transform pancreatic duct cells into islets.

Keywords: beta cell regeneration; immune protection; type 1 diabetes.

Copyright © 2013 John Wiley & Sons, Ltd.

Figures

Figure 1
Figure 1
A novel proposal to tackle type 1 diabetes at diagnosis

References

    1. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;17;318(11):663–6670.
    1. De Filippo G, Carel JC, Boitard C, et al. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes. 1996;45(1):101–104.
    1. Assan R, Blanchet F, Feutren G, et al. Normal renal function 8 to 13 years after cyclosporin. A therapy in 285 diabetic patients. Diabetes Metab Res Rev. 2002;18(6):464–472.
    1. Brandt C, Pavlovic V, Radbruch A, Worm M, et al. Low-dose cyclosporine. A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy. 2009;64(11):1588–1596.
    1. Levetan CS, Pierce SM. Distinctions between the islets of mice and men: implications for new therapies for type 1 and 2 diabetes. Endocr Pract. 2013;19(2):301–312.
    1. Li J, Wang Y, Yu X, Chen H. Islet neogenesis-associated protein-related pentadecapeptide enhances the differentiation of islet-like clusters from human pancreatic duct cells. Peptides. 2009;30(12):2242–2249.
    1. Levetan CS, Upham LV, Deng S, et al. Discovery of a human peptide sequence signaling islet neogenesis. Endocr Pract. 2008;14(9):1075–1083.
    1. Kapur R, Højfeldt TW, Mogensen JP. Short-term effects of INGAP and Reg family peptides on the appearance of small b-cells clusters in non-diabetic mice. Islets. 2012;4(1):1–9.
    1. Dungan KM, Buse JB, Ratner RE. Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP) Diabetes Metab Res Rev. 2009;25:558–565.
    1. Wang TC, Bonner-Weir S, Oates PS. Pancreatic gastrin stimulates islet differentiation of transforming growth factor a-induced ductular precursor cells. J Clin Invest. 1993;92:1349–1356.
    1. (Transition Therapeutics, March 5, 2007 Accessed January 1, 2013)
    1. Singh PK, Hota D, Dutta P. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2012;97(11):E2105–E2108.
    1. .
    1. .

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel